スナップチャート
The impact of GLP-1 weight-loss drugs on spending is significant: In the first six months after they start taking GLP-1s, US consumers on average spend 4% less on groceries and 5% less on fast food purchases, according to data from Pyxis, Bain & Company’s consumer intelligence division.
In the US today, about 15% of adults have tried GLP-1s, with 7% currently taking them, according to research based on Bain’s proprietary GLP-1 adoption model.
Growing penetration of GLP-1 drugs suggests that consumer food producers and restaurant brands must consider the impact of the drugs in their strategic planning. By 2030, as many as one in four US adults are expected to have tried GLP-1s, with 13%—nearly twice as many as today—taking them and another 15% as lapsed users. Previous Bain research has found that changes in consumer behavior often persist among those who stop taking the drugs.
About the Research
Data powered by Dynata, a leading global first-party data and insights platform.
Pyxis
Pyxis, Bain’s consumer analytics division, helps businesses navigate complex consumer landscapes and stay ahead of the competition. With one of the world’s largest ecosystems of transactional data, Pyxis has completed over 2,000 projects, delivering SKU-level visibility and uncovering shifts that drive growth, market share, loyalty, product development, M&A, and more.
First published in 1月 2026